HOOKIPA Pharma

HOOKPre-clinical

HOOKIPA Pharma's mission is to harness the power of the immune system to combat serious infectious diseases and cancers. Its core technology utilizes engineered replicating arenavirus vectors, both lymphocytic choriomeningitis virus (LCMV) and Pichinde virus (PICV), designed to elicit robust and durable antigen-specific CD8+ T cell responses. The company has advanced multiple candidates into clinical trials through internal development and strategic partnerships, including with Gilead Sciences and Roche, positioning itself at the forefront of next-generation immunotherapy platforms.

Market Cap

$10.4M

Employees

100-200

Focus

Biotech

HOOK · Stock Price

USD 1.0517.85 (-94.44%)

Historical price data

AI Company Overview

Technology Platform

Proprietary replicating arenavirus vector platforms (VaxWave® and TheraT®) engineered to elicit potent and durable antigen-specific CD8+ T cell responses for treating cancers and infectious diseases.

Funding History

Total raised: $185M

PIPE$50MGilead SciencesFeb 15, 2021

IPO$80MUndisclosedApr 15, 2019

Series B$35MSofinnova PartnersJun 15, 2017

Series A$20MSofinnova PartnersJun 15, 2014

Opportunities

HOOKIPA's primary growth opportunities lie in demonstrating clinical proof-of-concept for its arenavirus platform in late-line HPV+ head and neck cancer, which could unlock value across its broader oncology pipeline.

The lucrative partnerships in infectious diseases (HBV/HIV with Gilead) represent significant potential future milestone payments and royalties, providing a diversified path to value creation.

Risk Factors

Key risks include clinical trial failures for lead assets HB-200 and HB-300, which would critically devalue the platform.

The company also faces intense competition from larger biopharma firms with substantial resources, regulatory hurdles for novel immunotherapies, and the inherent financial risks of a pre-revenue company dependent on capital markets and partnership funding.

Competitive Landscape

HOOKIPA faces competition from other immunotherapy modalities, including cell therapies (e.g., TILs, TCR-T), mRNA vaccines, and other viral vector platforms in oncology. In infectious diseases, large pharma companies dominate. HOOKIPA's differentiation is its replicating arenavirus vector designed for superior CD8+ T cell induction, a mechanism validated by its partnerships with Gilead and Roche.